Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin

Vaccine

Volumn 27, Issue 34, 2009, Pages 4704-4708

  Vlahopoulos, Spiros ^a   Gritzapis, Angelo D ^a   Perez, Sonia A ^a   Cacoullos, Nike ^a   Papamichail, Michail ^a   Baxevanis, Constantine N ^a  

^a SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Glycosylation; HER 2; Herceptin; Yeast

Indexed keywords

ALPHA MANNOSIDASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MANNOSE; RECOMBINANT PROTEIN; TRASTUZUMAB;

ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DRUG ISOLATION; IMMUNOREACTIVITY; NONHUMAN; PICHIA PASTORIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING;

ANTIBODIES, MONOCLONAL; DENDRITIC CELLS; GLYCOSYLATION; HUMANS; MANNOSE; PICHIA; PROTEIN BINDING; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS;

EID: 67649464195     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.05.063     Document Type: Article

References (45)

1. Renard V., and Leach D.R. Perspectives on the development of a therapeutic HER-2 cancer vaccine. Vaccine 25 Suppl. 2 (2007) B17-23
2. Baxevanis C.N., Sotiropoulou P.A., Sotiriadou N.N., and Papamichail M. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 53 3 (2004) 166-175
3. Miller F., Jones R.F., Jacob J., Kong Y.C., and Wei W.Z. From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae. Breast Dis 20 (2004) 43-51
4. Mitchell M.S. Cancer vaccines, a critical review-part II. Curr Opin Investig Drugs 3 1 (2002) 150-158
5. Disis M.L., and Cheever M.A. HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol 18 1-2 (1998) 37-45
6. + T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 164 7 (2000) 3902-3912
7. + T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors. Cancer Immunol Immunother 52 12 (2003) 771-779
8. Mossman S.P., Evans L.S., Fang H., Staas J., Tice T., Raychaudhuri S., et al. Development of a CTL vaccine for Her-2/neu using peptide-microspheres and adjuvants. Vaccine 23 27 (2005) 3545-3554
9. Kiessling R., Wei W.Z., Herrmann F., Lindencrona J.A., Choudhury A., Kono K., et al. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 85 (2002) 101-144
10. Pilon S.A., Kelly C., and Wei W.Z. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J Immunol 170 3 (2003) 1202-1208
11. Correa I., and Plunkett T. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res 3 6 (2001) 399-403
12. Alegria M.C., Lavarda S.C., Lataro R.C., Hilario E., Ferro J.A., and Bertolini M.C. Conditions affecting production of functional muscle recombinant alpha-tropomyosin in Saccharomyces cerevisiae. Protein Expr Purif 30 1 (2003) 105-111
13. Jeong K.Y., Lee J., Lee I.Y., Hong C.S., Ree H.I., and Yong T.S. Expression of tropomyosin from Blattella germanica as a recombinant non-fusion protein in Pichia pastoris and comparison of its IgE reactivity with its native counterpart. Protein Expr Purif 37 2 (2004) 273-278
14. Pegram M.D., Konecny G., and Slamon D.J. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103 (2000) 57-75
15. Carter C.R., Keeble J.R., and Thorpe R. Human serum inactivates non-glycosylated but not glycosylated granulocyte colony stimulating factor by a protease dependent mechanism: significance of carbohydrates on the glycosylated molecule. Biologicals 32 1 (2004) 37-47
16. Sinclair A.M., and Elliott S. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94 8 (2005) 1626-1635
17. Tan M.C., Mommaas A.M., Drijfhout J.W., Jordens R., Onderwater J.J., Verwoerd D., et al. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur J Immunol 27 9 (1997) 2426-2435
18. Lam J.S., Mansour M.K., Specht C.A., and Levitz S.M. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J Immunol 175 11 (2005) 7496-7503
19. Luong M., Lam J.S., Chen J., and Levitz S.M. Effects of fungal N- and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine 25 22 (2007) 4340-4344
20. Lam J.S., Huang H., and Levitz S.M. Effect of differential N-linked and O-linked mannosylation on recognition of fungal antigens by dendritic cells. PLoS ONE 2 10 (2007) e1009
21. Berdy J., Bleomycin-Type, and Antibiotics. In: Berdy J. (Ed). In amino acid and peptide antibiotics (1980), CRC Press, Boca Raton, FL 459-497
22. Hamilton S.R., Bobrowicz P., Bobrowicz B., Davidson R.C., Li H., Mitchell T., et al. Production of complex human glycoproteins in yeast. Science 301 5637 (2003) 1244-1246
23. Sotiriadou R., Perez S.A., Gritzapis A.D., Sotiropoulou P.A., Echner H., Heinzel S., et al. Peptide HER2 (776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 85 10 (2001) 1527-1534
24. Macauley-Patrick S., Fazenda M.L., McNeil B., and Harvey L.M. Heterologous protein production using the Pichia pastoris expression system. Yeast 22 4 (2005) 249-270
25. Romanos M.A., Scorer C.A., and Clare J.J. Foreign gene expression in yeast: a review. Yeast 8 6 (1992) 423-488
26. Sreekrishna K., Potenz R.H., Cruze J.A., McCombie W.R., Parker K.A., Nelles L., et al. High level expression of heterologous proteins in methylotrophic yeast Pichia pastoris. J Basic Microbiol 28 4 (1988) 265-278
27. Paus E., and Steen H.B. Mitogenic effect of alpha-mannosidase on lymphocytes. Nature 272 5652 (1978) 452-454
28. Tulp A., Barnhoorn M., Bause E., and Ploegh H. Inhibition of N-linked oligosaccharide trimming mannosidases blocks human B cell development. EMBO J 5 8 (1986) 1783-1790
29. Ushakova N.A., Vlasova A.L., Preobrazhenskaia M.E., Samoǐlova R.S., Polianskaia A.M., Grigor'eva M.A., et al. Lymphoid cell glycosidases in various forms of lymphoproliferative disorders. Vopr Med Khim 37 6 (1991) 78-82
30. Vlasova A.L., Ushakova N.A., and Preobrazhenskaia M.E. Neutral alpha-mannosidase in human B- and T-lymphoid cells. Biokhimiia 56 8 (1991) 1479-1487
31. Yamada H., Nagai T., Takemoto N., Endoh H., Kiyohara H., Kawamura H., et al. Plantagoside, a novel alpha-mannosidase inhibitor isolated from the seeds of Plantago asiatica, suppresses immune response. Biochem Biophys Res Commun 165 3 (1989) 1292-1298
32. Desnick R.J., Sharp H.L., Grabowski G.A., Brunning R.D., Quie P.G., Sung J.H., et al. Mannosidosis: clinical, morphologic, immunologic, and biochemical studies. Pediatr Res 10 12 (1976) 985-996
33. Foy T.M., Bannink J., Sutherland R.A., McNeill P.D., Moulton G.G., Smith J., et al. Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine 19 17-19 (2001) 2598-2606
34. Lee J.Y., Kim D.H., Chung Y., Shin S.U., and Kang C.Y. Comparison of the antitumor efficacies of Her-2/neu DNA vaccines inducing contrasting IgG immunity but comparable CTL activity in mice. Vaccine 21 5-6 (2003) 521-531
35. Moran T.P., Burgents J.E., Long B., Ferrer I., Jaffee E.M., Tisch R.M., et al. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine 25 36 (2007) 6604-6612
36. Tu C.F., Lin C.C., Chen M.C., Ko T.M., Lin C.M., Wang Y.C., et al. Autologous neu DNA vaccine can be as effective as xenogenic neu DNA vaccine by altering administration route. Vaccine 25 August (4) (2007) 719-728 [Epub 2006]
37. Smorlesi A., Papalini F., Amici A., Orlando F., Pierpaoli S., Mancini C., et al. Evaluation of different plasmid DNA delivery systems for immunization against HER2/neu in a transgenic murine model of mammary carcinoma. Vaccine 24 11 (2006) 1766-1775
38. Quaglino E., Mastini C., Iezzi M., Forni G., Musiani P., Klapper L.N., et al. The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine 23 25 (2005) 3280-3287
39. Provinciali M., Smorlesi A., Donnini A., Bartozzi B., and Amici A. Low effectiveness of DNA vaccination against HER-2/neu in ageing. Vaccine 21 9-10 (2003) 843-848
40. Renard V., Sonderbye L., Ebbehøj K., Rasmussen P.B., Gregorius K., Gottschalk T., et al. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 171 3 (2003) 1588-1595
41. Pupa S.M., Iezzi M., Di Carlo E., Invernizzi A., Cavallo F., Meazza R., et al. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 65 3 (2005) 1071-1078
42. Manjili M.H., Wang X.Y., Chen X., Martin T., Repasky E.A., Henderson R., et al. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice. J Immunol 171 8 (2003) 4054-4061
43. Helguera G., Dela Cruz J.S., Lowe C., Ng P.P., Trinh R., Morrison S.L., et al. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. Vaccine 24 3 (2006) 304-316
44. Dela Cruz J.S., Morrison S.L., and Penichet M.L. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine 23 39 (2005) 4793-4803
45. Dela Cruz J.S., Lau S.Y., Ramirez E.M., De Giovanni C., Forni G., Morrison S.L., et al. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 21 13-14 (2003) 1317-1326